GRI Bio Inc. Cash Flow Conversion Efficiency
GRI Bio Inc. cash flow conversion efficiency. Based on the latest financial reports, GRI Bio Inc. (GRI) has a cash flow conversion efficiency ratio of -0.141x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.45 Million) by net assets ($10.28 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of GRI Bio Inc. (2018–2025)
Cash flow conversion efficiency of GRI Bio Inc. from 2018 to 2025. This chart illustrates how GRI Bio Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View GRI stock price and chart for real-time trading data and today's change.
GRI Bio Inc. Cash Flow Conversion Ratio Explained
GRI Bio Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
GRI Bio Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GRI Bio Inc. ranked by their cash flow conversion efficiency. Also see market cap of GRI Bio Inc. for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Immersion SA
PA:ALIMR
|
0.089x |
|
GuocoLand (Malaysia) Bhd
KLSE:1503
|
-0.003x |
|
IMMO BLOCKCHAIN EO 1
F:QT5
|
N/A |
|
Vertu Motors Plc
LSE:VTU
|
0.044x |
|
Lithium Universe Ltd
AU:LU7
|
0.447x |
|
EVE Health Group Limited
AU:EVE
|
-0.242x |
|
REDSUN PROPERTIES GROUP
F:0RJ
|
N/A |
|
PreveCeutical Medical Inc
F:18H
|
0.070x |
Annual Cash Flow Conversion Efficiency for GRI Bio Inc. (2018–2025)
The table below shows the annual cash flow conversion efficiency of GRI Bio Inc. from 2018 to 2025. Review GRI Bio Inc. (GRI) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $6.01 Million | $-10.19 Million | -1.695x | +20.61% |
| 2024-12-31 | $4.03 Million | $-8.61 Million | -2.136x | +93.85% |
| 2023-12-31 | $259.00K | $-8.99 Million | -34.710x | -5298.57% |
| 2022-12-31 | $-1.62 Million | $-1.08 Million | 0.668x | -62.05% |
| 2021-12-31 | $-4.72 Million | $-8.31 Million | 1.760x | -30.97% |
| 2020-12-31 | $-1.45 Million | $-3.71 Million | 2.549x | +384.06% |
| 2019-12-31 | $3.21 Million | $-2.88 Million | -0.897x | +94.21% |
| 2018-12-31 | $152.94K | $-2.37 Million | -15.503x | -- |
About GRI Bio Inc.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung … Read more